Format

Send to

Choose Destination
Cancer Epidemiol Biomarkers Prev. 2018 Mar;27(3):321-330. doi: 10.1158/1055-9965.EPI-17-0434. Epub 2018 Jan 16.

Genetic Variants in Immune-Related Pathways and Breast Cancer Risk in African American Women in the AMBER Consortium.

Author information

1
Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, New York. Chi-Chen.Hong@RoswellPark.org.
2
College of Pharmacy, The Ohio State University, Columbus, Ohio.
3
Department of Biostatistics and Bioinformatics, Roswell Park Cancer Institute, Buffalo, New York.
4
Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, New York.
5
Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts.
6
Slone Epidemiology Center at Boston University, Boston, Massachusetts.
7
University of Michigan School of Public Health, Ann Arbor, Michigan.
8
Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
9
Department of Epidemiology, College of Public Health and Health Professions & College of Medicine, University of Florida, Gainsville, Florida.
10
Cancer Prevention and Control, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey.
11
Department of Preventive Medicine, Keck School of Medicine, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, California.
12
Department of Immunology, Roswell Park Cancer Institute, Buffalo, New York.

Abstract

Background: Constitutional immunity shaped by exposure to endemic infectious diseases and parasitic worms in Sub-Saharan Africa may play a role in the etiology of breast cancer among African American (AA) women.Methods: A total of 149,514 gene variants in 433 genes across 45 immune pathways were analyzed in the AMBER consortium among 3,663 breast cancer cases and 4,687 controls. Gene-based pathway analyses were conducted using the adaptive rank truncated product statistic for overall breast cancer risk, and risk by estrogen receptor (ER) status. Unconditional logistic regression analysis was used to estimate ORs and 95% confidence intervals (CIs) for single variants.Results: The top pathways were Interleukin binding (P = 0.01), Biocarta TNFR2 (P = 0.005), and positive regulation of cytokine production (P = 0.024) for overall, ER+, and ER- cancers, respectively. The most significant gene was IL2RB (P = 0.001) for overall cancer, with rs228952 being the top variant identified (OR = 0.85; 95% CI, 0.79-0.92). Only BCL3 contained a significant variant for ER+ breast cancer. Variants in IL2RB, TLR6, IL8, PRKDC, and MAP3K1 were associated with ER- disease. The only genes showing heterogeneity between ER- and ER+ cancers were TRAF1, MAP3K1, and MAPK3 (P ≤ 0.02). We also noted genes associated with autoimmune and atopic disorders.Conclusions: Findings from this study suggest that genetic variants in immune pathways are relevant to breast cancer susceptibility among AA women, both for ER+ and ER- breast cancers.Impact: Results from this study extend our understanding of how inherited genetic variation in immune pathways is relevant to breast cancer susceptibility. Cancer Epidemiol Biomarkers Prev; 27(3); 321-30. ©2018 AACR.

PMID:
29339359
PMCID:
PMC5835191
[Available on 2019-03-01]
DOI:
10.1158/1055-9965.EPI-17-0434

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center